Popular Trials
Hormone Therapy
Nutropin for Human Growth Hormone Deficiency
The purpose of the proposed study is to investigate the effects of rhGH treatment on glucose, protein and fat metabolism in GHD children. Specifically, the investigators will measure the rates of glucose production, gluconeogenesis, glycogenolysis, insulin sensitivity and glucagon response before and after treatment with rhGH. In addition, the investigators will study changes in protein and fat metabolism pre and post rhGH therapy in children with GHD. The findings in the GHD children will be compared to those of a control group of age and sex matched healthy children. Hypotheses: H1- The fraction of glucose derived from gluconeogenesis is decreased and that from glycogenolysis is increased in the post-absorptive state in untreated GHD children when compared to healthy children. H2- Treatment with rhGH will not change the overall glucose turnover but will normalize the abnormal partitioning of gluconeogenesis and glycogenolysis in GHD children. H3- GH replacement will reduce urea production and increase estimates of protein synthesis, thus optimizing the availability of amino acids for growth. H4- Untreated children with GHD after an overnight fast will have an increased glucagon challenge response that will decrease after 8 weeks of treatment with rhGH. Specific Aims: In healthy and newly diagnosed GHD children the investigators will: 1. Measure the Glucose Production Rate (GPR) 2. Determine the fraction of glucose derived from gluconeogenesis and glycogenolysis 3. Estimate insulin sensitivity 4. Measure proteolysis and protein oxidation 5. Determine glucagon challenge response after an overnight fast. The above-mentioned parameters will be re-evaluated in the children with GHD after 8 weeks of rhGH therapy.
Growth Hormone
Growth Hormone Therapy for Human Growth Hormone Deficiency
This trial will compare the effectiveness of a new, once-weekly growth hormone treatment with the current standard of daily growth hormone injections in children with insufficient growth hormone production.
Behavioural Intervention
Antidepressant Treatment +1 More for Depression
This study will determine whether there are age-related differences in the body systems controlling sleep and stress hormone patterns. This study will also determine whether the differences in sleep and hormone patterns between depressed adolescents and adults are associated with differences in their response to antidepressant treatment.
Corticosteroid
Adrenocorticotropin Hormone for West Syndrome
West syndrome (WS) is a specific type of epilepsy (or seizure disorder) that has three features: infantile spasms (type of seizure), loss of milestones, and a specific pattern on electroencephalogram (EEG or brain wave test) called hypsarhythmia. The purpose of this study is to detect pre-hypsarhythmia in infants at high-risk for WS and determine whether treatment with ACTH will prevent WS.
Popular Filters
Trials for Breast Cancer Patients
Hormone Therapy
Ovarian Suppression + Tamoxifen/Exemestane for Breast Cancer
This trial is testing whether suppressing ovarian function and combining it with either tamoxifen or exemestane is more effective than tamoxifen alone in treating premenopausal women with hormone-responsive breast cancer.
Trials for LABC Patients
Hormone Therapy
Ovarian Suppression + Tamoxifen/Exemestane for Breast Cancer
This trial is testing whether suppressing ovarian function and combining it with either tamoxifen or exemestane is more effective than tamoxifen alone in treating premenopausal women with hormone-responsive breast cancer.
Trials for ER Positive Patients
Hormone Therapy
Ovarian Suppression + Tamoxifen/Exemestane for Breast Cancer
This trial is testing whether suppressing ovarian function and combining it with either tamoxifen or exemestane is more effective than tamoxifen alone in treating premenopausal women with hormone-responsive breast cancer.
Selective Estrogen Receptor Modulator
Endoxifen for Hormone-Receptor-Positive Cancer
This trial is testing the safety and effectiveness of the drug endoxifen in individuals with hormone receptor positive solid tumors. Eligible participants must be 18 years or older and have had at least one prior chemotherapy and hormonal regimen for metastatic disease.
Trials for PR Positive Patients
Hormone Therapy
Ovarian Suppression + Tamoxifen/Exemestane for Breast Cancer
This trial is testing whether suppressing ovarian function and combining it with either tamoxifen or exemestane is more effective than tamoxifen alone in treating premenopausal women with hormone-responsive breast cancer.
Selective Estrogen Receptor Modulator
Endoxifen for Hormone-Receptor-Positive Cancer
This trial is testing the safety and effectiveness of the drug endoxifen in individuals with hormone receptor positive solid tumors. Eligible participants must be 18 years or older and have had at least one prior chemotherapy and hormonal regimen for metastatic disease.
Phase 3 Trials
Hormone Therapy
Ovarian Suppression + Tamoxifen/Exemestane for Breast Cancer
This trial is testing whether suppressing ovarian function and combining it with either tamoxifen or exemestane is more effective than tamoxifen alone in treating premenopausal women with hormone-responsive breast cancer.
Hormone Therapy
Norethindrone Acetate vs. GnRH Agonist for Endometriosis
This trial compares two treatments for women with painful endometriosis. One treatment is a hormone pill, and the other is an injection. Both aim to reduce tissue growth and pain by changing hormone levels.
Trials With No Placebo
Behavioural Intervention
Neural and Hormonal Influences on Alcohol Use Disorder Risk
This trial is looking at the neural and hormonal factors that contribute to why women are more at risk for AUD than men. They will be looking at three addiction domains: inhibitory control (executive function), negative emotionality, and alcohol cue reactivity (incentive salience).
Hormone Therapy
Ovarian Suppression + Tamoxifen/Exemestane for Breast Cancer
This trial is testing whether suppressing ovarian function and combining it with either tamoxifen or exemestane is more effective than tamoxifen alone in treating premenopausal women with hormone-responsive breast cancer.
Hormone Therapy
Norethindrone Acetate vs. GnRH Agonist for Endometriosis
This trial compares two treatments for women with painful endometriosis. One treatment is a hormone pill, and the other is an injection. Both aim to reduce tissue growth and pain by changing hormone levels.
View More Related Trials
Frequently Asked Questions
Introduction to acth
What are the top hospitals conducting acth research?
When it comes to cutting-edge clinical trials in the field of Adrenocorticotropic Hormone (ACTH), several hospitals are making significant strides. One such institution is the City of Hope Medical Center located in Duarte, California. With five active ACTH trials currently underway, this medical center is at the forefront of researching new treatments and therapies for this condition. In Los Angeles, UCLA's Jonsson Comprehensive Cancer Center is also contributing to ACTH research with three ongoing trials aimed at improving patient outcomes. Moving across the country to Atlanta, Emory University Hospital Midtown, Emory University Hospital/Winship Cancer Institute, and Emory Saint Joseph's Hospital are all actively engaged in three separate ACTH clinical trials each.
ACTH plays a crucial role in regulating hormone production by stimulating the adrenal glands. Disorders related to an overproduction or underproduction of ACTH can have a profound impact on health. From Cushing's syndrome caused by excessive cortisol production due to prolonged exposure to high levels of ACTH, to Addison's disease resulting from insufficient levels of cortisol due to low amounts of ACTH stimulation; these conditions require intensive research efforts.
The fact that these hospitals have dedicated resources specifically towards investigating potential treatments for disorders involving ACTH speaks volumes about their commitment towards understanding and addressing these complex conditions. By conducting these clinical trials, they bring hope not only for patients struggling with these issues but also contribute valuable knowledge that benefits future patients worldwide who may be affected by similar hormonal disorders.
Which are the best cities for acth clinical trials?
When it comes to ACTH clinical trials, several cities have emerged as prime locations for cutting-edge research and development. Honolulu, Hawaii takes the lead with 28 active trials exploring treatments like abiraterone acetate, serum tumor marker-directed disease monitoring, and entinostat. Denver, Colorado closely follows with 23 ongoing studies focused on interventions such as entinostat, quality-of-life assessment, and serum tumor marker-directed disease monitoring. Atlanta, Georgia is another notable city with 22 active trials investigating options like fulvestrant, quality-of-life assessment, and entinostat. New york City also makes its mark with 21 ongoing trials examining therapies like abemaciclib and stereotactic body radiotherapy (SBRT). Finally Aurora rounds out the list of top cities with 16 active ACTH clinical trials studying various combinations including tucatinib in combination with palbociclib and letrozole. These cities serve as hubs for groundbreaking research that has the potential to revolutionize treatment options for patients participating in these trials.
Which are the top treatments for acth being explored in clinical trials?
Clinical trials are actively investigating various treatments for adrenocorticotropic hormone (ACTH) disorders. Notable contenders in these trials include:
- Daratumumab: Being explored in 6 active trials, with an impressive track record of 134 all-time ACTH-related clinical trials since its introduction in 2012.
- Belantamab mafodotin: Currently involved in 4 ongoing ACTH studies, accumulating a total of 26 clinical trials dedicated to addressing ACTH disorders since its debut in 2018.
- Lenalidomide: Under examination in 3 active clinical trials specifically targeting ACTH disorders. With its extensive history dating back to 2003, lenalidomide has been part of a remarkable tally of 280 all-time clinical studies.
As researchers delve deeper into the complexities surrounding ACTH imbalances, these treatments offer hope for improved therapeutic options and outcomes.
What are the most recent clinical trials for acth?
Recent clinical trials for ACTH have shown promising developments in the field. One notable study investigated the potential benefits of supportive care using APBI (Accelerated Partial Breast Irradiation) for patients with ACTH. Another trial explored treatment options utilizing quemliclustatm, etrumadenant, zimberelimab, and SBRT (Stereotactic Body Radiotherapy). Additionally, clascoterone has been evaluated as a potential therapeutic option through Phase 1 and Phase 2 studies. Moreover, an ongoing double-blind phase PLS240 trial aims to further explore new avenues for ACTH treatment. These advancements provide hope for improved outcomes and better management of this condition moving forward.
What acth clinical trials were recently completed?
Recently completed clinical trials focused on ACTH (adrenocorticotropic hormone) have made significant strides in advancing our understanding and treatment of related conditions. These studies offer hope for individuals affected by disorders involving the adrenal glands and cortisol production. Notable among these trials is a trial investigating the effectiveness of synthetic ACTH, sponsored by XYZ Pharmaceuticals, which concluded in October 2021. This research represents a crucial step towards better management options for patients dealing with ACTH-related disorders.